Tirofiban
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tirofiban
Tirofiban: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication with a score of 0.99 or higher for Tirofiban, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| acute coronary syndrome |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 8350L | Aggrastat | Solution concentrate for I.V. infusion 1 | Valid |
Safety Considerations
- Contraindications suggested by the knowledge graph (disease associations, not label text): thrombocytopenia, blood coagulation disease, stroke disorder, cerebrovascular disorder, susceptibility to ischaemic stroke, cerebral infarction, injury, brain cancer, brain neoplasm, intracranial haemorrhage, and arteriovenous malformation.
- Drug interactions (100 recorded; main ones shown):
- Major: abciximab, deferasirox, acalabrutinib, ibritumomab tiuxetan, tositumomab (including I-131), trastuzumab emtansine.
- Moderate: acetylsalicylic acid, ketorolac (including ophthalmic), ibuprofen, dexfenfluramine, fenfluramine, sibutramine.
- Specific concern for the predicted indication: tirofiban-induced thrombocytopenia has been documented in the literature above, and added antiplatelet effect is likely harmful in bleeding disorders.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.